Antioxidant-Free Bendamustine Liquid Compositions for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bendamustine hydrochloride is prone to rapid hydrolysis, photolytic, and oxidative degradation in aqueous solutions, leading to instability and the need for complex lyophilized formulations that are cumbersome to use and risk microbial contamination, with existing liquid formulations requiring antioxidants that can cause adverse reactions.
Innovation Solution
Development of stable, antioxidant-free, ready-to-use or ready-to-dilute liquid compositions of bendamustine using non-aqueous solvents like polyethylene glycol and dehydrated alcohol, with controlled oxygen levels and pH adjustment, eliminating the need for inert gas purging and ensuring long-term stability and reduced impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If lyophilized formulations are used to prevent hydrolytic degradation, then stability is improved, but ease of operation deteriorates due to cumbersome reconstitution process and risk of microbial contamination
Solution Approach 1:
The patent changes the physical state parameter from solid lyophilized powder to liquid formulation, and modifies the chemical composition by using non-aqueous solvents (polyethylene glycol, dehydrated alcohol) instead of water, thereby achieving both stability and ease of operation without reconstitution
Solution Approach 2:
The patent introduces non-aqueous solvents as intermediary substances that replace water as the solvent medium, preventing hydrolytic degradation while maintaining liquid formulation properties that eliminate reconstitution requirements and reduce microbial contamination risks
2Stability of the object's composition
If antioxidants are added to prevent oxidative degradation, then stability is improved, but object-generated harmful factors worsen due to adverse reactions from antioxidants
Solution Approach 1:
The patent converts the harmful effect of oxygen presence by using non-aqueous solvents with different chemical properties that create a different degradation profile, allowing stability without antioxidants and avoiding their harmful side effects
Solution Approach 2:
The patent changes the solvent composition parameter from aqueous to non-aqueous (polyethylene glycol and dehydrated alcohol), which fundamentally alters the degradation mechanisms and eliminates the need for antioxidants
3Ease of manufacture
If aqueous solutions are used for formulation, then ease of manufacture is improved, but stability deteriorates due to rapid hydrolysis and oxidative degradation
Solution Approach 1:
The patent changes the fundamental parameter of solvent type from aqueous to non-aqueous, specifically using polyethylene glycol and dehydrated alcohol, which maintains ease of manufacture while dramatically improving stability by preventing hydrolysis and oxidation
Solution Approach 2:
The patent uses a composite solvent system comprising polyethylene glycol and dehydrated alcohol in specific proportions, creating a stable liquid formulation that combines the benefits of both components while maintaining ease of manufacture
4Stability of the object's composition
If non-aqueous solvents are used to improve stability, then stability is improved, but device complexity increases due to need for controlled oxygen levels and pH adjustment
Solution Approach 1:
The patent optimizes specific parameters including pH adjustment to alkaline range (9.0-10.5) and controlled oxygen levels through nitrogen purging, which simplifies the formulation approach by establishing clear parameter targets rather than requiring complex stabilization systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions maintain stability for at least 6 months at 2-8°C with reduced impurities, minimizing infusion-related adverse events and simplifying administration by avoiding antioxidants, thus ensuring effective and safe treatment of conditions like chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Implementation Method 1
Bendamustine hydrochloride undergoes hydrolysis rapidly in aqueous solution by direct substitution rather than an addition elimination process
Implementation Method 2
Bendamustine also undergoes photolytic and oxidative degradation
Implementation Method 3
Bendamustine also undergoes photolytic and oxidative degradation
Data Source
AI summary
Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.